Journal
PHARMACEUTICS
Volume 13, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13091500
Keywords
epidermal growth factor receptor tyrosine kinase inhibitors; EGFR mutations; molecular targeted therapy; non-small cell lung cancer; resistance mechanism
Categories
Funding
- Research Project (College subject) of Mianyang Central Hospital [2020FH02]
- Research Project of Application Development and Scientific Achievements Transformation in Chengdu Medical College [CYCG19-03]
Ask authors/readers for more resources
Molecular targeted therapy offers a more precise approach to treating NSCLC patients with EGFR mutations. Various therapeutic agents targeting EGFR mutations have been approved or are in clinical trials worldwide, showing promise for a more personalized and effective treatment strategy.
Molecular targeted therapy has been reported to have fewer adverse effects, and offer a more convenient route of administration, compared with conventional chemotherapy. With the development of sequencing technology, and research on the molecular biology of lung cancer, especially whole-genome information on non-small cell lung cancer (NSCLC), various therapeutic targets have been unveiled. Among the NSCLC-driving gene mutations, epidermal growth factor receptor (EGFR) mutations are the most common, and approximately 10% of Caucasian, and more than 50% of Asian, NSCLC patients have been found to have sensitive EGFR mutations. A variety of targeted therapeutic agents for EGFR mutations have been approved for clinical applications, or are undergoing clinical trials around the world. This review focuses on: the indications of approved small molecular kinase inhibitors for EGFR mutation-positive NSCLC; the mechanisms of drug resistance and the corresponding therapeutic strategies; the principles of reasonable and precision molecular structure; and the drug development discoveries of next-generation inhibitors for EGFR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available